Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Efficacy and safety of zanubrutinib, rituximab, and venetoclax combination regimen in previously untreated follicular lymphoma: A Phase II trial from the bbc study

View Full Paper
Ask AI
Bookmark
Share

Authors

JSJinhong ShiYLYang Liu

Discussion

Loading...

Member takes

Overview

Phase II trial demonstrates high complete response rate in patients with follicular lymphoma, suggesting kinase inhibitors may enhance treatment efficacy.

Key Points

  • Treatment with zanubrutinib and venetoclax achieved a complete response rate of 100% in three patients after six cycles.
  • Combined therapy effectively targets follicular lymphoma and may improve patient outcomes; safety profile remains favorable with predominantly low-grade side effects.
  • Observational trial at a single-center enrolled 30 adult patients with previously untreated follicular lymphoma to assess treatment effectiveness and safety.
  • Combining kinase inhibitors with rituximab shows promise, necessitating larger trials to confirm findings and evaluate long-term outcomes.

Cite This Study

Shi et al. (2025) studied this question.

synapsesocial.com/papers/69362f574fa91c937236da2ahttps://doi.org/10.1182/blood-2025-7108
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Zanubrutinib combined with bendamustine and rituximab in previously untreated patients with advanced follicular lymphoma: A prospective, open-label, single-arm phase II clinical study2025
  2. 2Zanubrutinib plus obinutuzumab induces promising efficacy and a manageable safety profile in previously untreated high-tumor-burden follicular lymphoma2025
  3. 3A Phase II trial of obinutuzumab, ibrutinib and venetoclax in patients with previously untreated follicular lymphoma; A University of California hematologic malignancies consortium study2025
  4. 4Efficacy and safety of zanubrutinib combined with anti-CD20 monoclonal antibody-based regimens as first-line therapy in high-risk follicular lymphoma and marginal zone lymphoma: A single-arm retrospective study2025
  5. 5Efficacy and safety of zanubrutinib combination therapy and monotherapy maintenance in patients with follicular lymphoma: A retrospective single-center analysis2025